Applications of Curcumin and Its Nanoforms in the Treatment of Cancer

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(9), P. 2223 - 2223

Published: Aug. 29, 2023

Due to the diverse medicinal and pharmacokinetic properties of turmeric, it is well-known in therapeutic, pharmaceutic, nutraceutical, cosmetic, dietary industries. It gained importance due its multitude properties, such as wound-healing, anti-inflammatory, anti-oxidant, anti-microbial, cytoprotective, anti-aging, anti-cancer, immunomodulatory effects. Even though natural healing effect turmeric has been known Indians early 2500 BCE, global demand for increased only recently. A major reason beneficiary activities presence yellow-colored polyphenolic compound called curcumin. Many studies have carried out on various curcumin derivatives. Despite low bioavailability, effectively used treatment many diseases, cardiovascular neurological diabetes, arthritis, cancer. The advent nanobiotechnology further opened wide opportunities explore expand use medical field. Nanoformulations using derivatives helped design new modalities, specifically cancer, because better bioavailability solubility nanocurcumin when compared This review deals with applications nanoparticles cancer therapy broadly tries understand how affect immunological status cell.

Language: Английский

---

Recent Developments in Nanoparticle‐Based Photo‐Immunotherapy for Cancer Treatment

Small Methods, Journal Year: 2023, Volume and Issue: 7(5)

Published: March 24, 2023

Phototherapy is an emerging approach for cancer treatment that effective at controlling the growth of primary tumors. In presence light irradiation, photothermal and photodynamic agents are delivered to tumor sites can induce local hyperthermia production reactive oxygen species, respectively, directly eradicate cells. Nanoparticles, characterized by their small size tunable physiochemical properties, have been widely utilized as carriers phototherapeutic improve biocompatibility tumor-targeted delivery. Nanocarriers also be used implement various codelivery strategies further enhancing efficiency. More recently, there has considerable interest in augmenting immunological effects nanoparticle-based phototherapies, which yield durable systemic antitumor responses. This review provides overview recent developments using nanoparticle technology achieve photo-immunotherapy.

Language: Английский

---

Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects

ONCOLOGIE, Journal Year: 2024, Volume and Issue: 26(1), P. 9 - 25

Published: Jan. 1, 2024

Abstract Hepatocellular carcinoma (HCC) is a concerning liver cancer with rising incidence and mortality rates worldwide. The effectiveness of traditional therapies in managing advanced HCC limited, necessitating the development new therapeutic strategies. Immune checkpoint inhibitors (ICIs) have emerged as promising strategy for management. By preventing tumor cells from evading immune surveillance through immunological checkpoints, ICIs can restore system’s ability to target eliminate tumors. While show promise enhancing response against malignancies, challenges such drug resistance adverse reactions hinder their efficacy. To address these challenges, developing individualized ICI treatment strategies critical. Combining targeted therapy immunotherapy holds potential comprehensive effects. Additionally, biomarker-based offer predicting guiding personalized patient care. Future research should explore emerging methods optimize immunotherapy. This review provides an overview HCC, demonstrating some success promoting response. However, remain important considerations that must be addressed. As tailored plans evolve, prospect expected grow, offering opportunities improved outcomes.

Language: Английский

---

Cellular and molecular basis of proximal small intestine disorders

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(10), P. 687 - 709

Published: Aug. 8, 2024

Language: Английский

---

Deletion of IL-6 Exacerbates Colitis and Induces Systemic Inflammation in IL-10-Deficient Mice

Journal of Crohn s and Colitis, Journal Year: 2019, Volume and Issue: 14(6), P. 831 - 840

Published: Oct. 30, 2019

Abstract Background and Aims Interleukin 6 [IL-6] or its receptor is currently a candidate for targeted biological therapy of inflammatory bowel disease [IBD]. Thus, comprehensive understanding the consequences blocking IL-6 imperative. We investigated this by evaluating effects deletion on spontaneous colitis IL-10-deficient mice [IL-10−/−]. Methods IL-6/IL-10 double-deficient [IL-6−/−/IL-10−/−] were generated analysed intestinal inflammation, general phenotypes molecular/biochemical changes in colonic mucosa compared with wild-type IL-10−/− mice. Results Unexpectedly, IL-6−/−/IL-10−/− showed more pronounced gut inflammation earlier onset than mice, both locally [colon small bowel] systemically [splenomegaly, ulcerative dermatitis, leukocytosis, neutrophilia monocytosis]. exhibited elevations multiple cytokines [IL-1β, IL-4, IL-12, TNFα] chemokines [MCP-1 MIG], but not IFN-γ [Th1], IL-17A IL-17G [Th17], IL-22 [Th22]. FOXP3 TGF-β, two key factors regulatory T [Treg] cell differentiation, significantly down-regulated mucosa, thymus mesenteric lymph nodes, CTLA-4 was diminished while iNOS up-regulated Conclusion In complete blockade aggravates at least part suppressing Treg/CTLA-4 promoting IL-1β/Th2 pathway. addition, double mutant exhibits signs severe systemic inflammation. Our data define new function suggest that caution should be exercised when targeting IBD patients, particularly those defects IL-10 signalling.

Language: Английский

---